Ignite Creation Date:
2024-05-19 @ 5:33 PM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06419179
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-17
First Post:
2024-05-03
Brief Title:
Maintenance Durvalumab MEDI4736 and Olaparib AZD2281 After Standard 1st Line Treatment CarboplatinCisplatin Etoposide Durvalumab in HRD Positive Extensive Disease ED Small-cell Lung Cancer SCLC
Sponsor:
University of Cologne
Organization:
University of Cologne
Organization Data
Organization:
University of Cologne
Class:
OTHER
Study ID:
Uni-Koeln-5159
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
University of Cologne
Lead Sponsor Class:
OTHER
Responsible Party:
Prof Dr Juergen Wolf
Responsible Party Title:
Clinical Prof Dr Jürgen Wolf
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
University of Cologne
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| AstraZeneca | INDUSTRY |